Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection

Lung

Volumn 180, Issue 5, 2002, Pages 273-279

  Yeh, J J ^a   Liu, F Y ^b   Hsu, W H ^c   Wang, J J ^d   Ho, S T ^e   Kao, A ^c  

^a PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Adenocarcinoma; Cytokeratin fragment 19 (CYFRA 21 1); Squamous cell carcinoma

Indexed keywords

CYTOKERATIN 19; ANTIGEN CYFRA21.1; KERATIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; BLOOD; LUNG TUMOR; MIDDLE AGED; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0036356201     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004080000101     Document Type: Article

References (28)

1. Bates SE (1991) Clinical applications of serum markers. Ann Intern Med 115:623-628
2. Bodenmuller H, Banauch D, Ofenloch B, Jaworek D, Dessauer A (1992) Technical evaluation of a new automated tumor marker assay: the enzyme-test CYFRA 21-1. In: Klapdor R (ed) Tumor-associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the 90th. Verlag, Zuckschwerdt, pp 37-138
3. Bodenmuller H, Ofenloch Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F (1994) Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay enzymun-test CYFRA 21-1. Int J Biol Markers 9:75-81
4. Broers JL, Ramaekers FC, Rot MK, Oostendrop T, Huysmans A, van-Muijen GN, Wagenaar SS, Vooijs GP (1988) Cytokeratins in different types of human lung as monitored by chain-specific monoclonal antibodies. Cancer Res 48:3221-3229
5. Broers JL, Rot MK, Oostendrop T, Huysmans A, Wagenaar SS, Wiersma-van-Tilburg AJ, Vooijs GP, Ramaekers FC (1987) Immunohistochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal and neuroendocrine antigens. Cancer Res 47:3225-3234
6. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A (1987) Tumour marker in bronchogenic carcinoma: superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 60:42-50
7. Buccheri GF, Ferrigo D (1988) Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer. Chest 93:565-570
8. Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F (1986) Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 57:2389-2396
9. Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SL (1985) Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 52:333-338
10. Debus E, Moll R, Franke WW, Weber K, Osborn M (1984) Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 114:121-130
11. Ebert W, Dienemann H, Fateh-Moghadam A (1994) Cytokeratin 10 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer: results of an international multicenter study. Eur J Clin Chem Clin Biochem 32:189-199
12. Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E (1999) Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 19:3613-3618
13. Habets JM, Tank B, Vuzevski VD, Breve J, van-der-Kwast T, van-Joost T (1989) Immunoelectron microscopic studies on cytokeratins in human basal cell carcinoma. Anticancer Res 9:65-70
14. Hasholzner U, Stieber P, Fiebig M, Sunder-Plassmann L, Fateh-Moghadam A (1992) CYFRA: a new tumor marker for non-small cell lung cancer (NSCLC). In: Klapdor R (ed) Tumor-associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Cancer of the breast - state and trends in diagnosis and therapy. W. Zuckschwerdt Verlag München, Bern, Wein, pp 134-136
15. Huang MS, Jong SB, Tsai MS, Lin MS, Chong IW, Lin HC, Hwang JJ (1997) Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir Med 91:135-142
16. Kao CH, Hsieh JF, Ho YJ, Ding HJ (1999) Cytokeratin fragment (CYFRA 21-1) and carcino-embryonic antigen for early prediction of recurrence of lung adenocarcinoma. Lung 177:333-337
17. Kasper M, Stosiek P, Typlt H, Karsten U (1987) Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol 23:137-147
18. Menendez-Botet CJ, Oettgen HF, Pinsky CM, Schwartz MK (1978) A preliminary evaluation of tissue poltpeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasm. Clin Chem 24:868-872
19. Muller GF, Marshall RJ, Cooper EH, Waston DA, Walker DA, Mearns AJ (1985) The role of serum tumor markers to aid the selection of lung cancer patients for surgery and assessment of prognosis. Eur J Cancer Clin Oncol 12:1461-1466
20. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J (1995) Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 8:291-294
21. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A (1995) Clinical evaluation of seven tumor markers in lung cancer diagnosis: Can any combination improve the results? Br J cancer 72:170-173
22. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB (1993) Serum fragment of cytokeratin Subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53:61-66
23. Rastel D, Ramaioli A, Cornillie F (1994) Thirion B on behalf of the CYFRA 21-1 mutlicentric study group. CYFRA 21-1: a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur J Cancer 5:601-606
24. Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheld HH, Broermann P, Berdel WE, Macha HN, Thomas M (2002) Prognostic impact of Cyfra 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36:265-270
25. Spiro SG (1988) Prognosis and end results. In: Hoogastraten B, Addis BJ, Hansen HH, Martini N, Spiro SG (eds) Lung tumors. Springer-Verlag, Berlin, pp 163-166
26. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH (2000) Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. Am J Clin Oncol 23:241-243
27. Tan Y, Zhang P, Zheng C (1999) Usefulness of CYFRA 21-1 as a tumor marker of non-small-cell lung cancer. Zhonghua Zhong Liu Za Zi 21:287-289
28. Vincent RG, Chu TM, Lane WW (1979) The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 42:685-691